Dihydropyrimidine Dehydrogenase Levels in Colorectal Cancer Cells Treated with a Combination of Heat Shock Protein 90 Inhibitor and Oxaliplatin or Capecitabine

Dihydropyrimidine Dehydrogenase Levels in Colorectal Cancer Cells Treated with a Combination of Heat Shock Protein 90 Inhibitor and Oxaliplatin or Capecitabine

Purpose: Dihydropyrimidine dehydrogenase (DPD) is the principal enzyme in the catabolism of fluoropyrimidine drugs including capecitabine. A recent report has suggested that oxaliplatin chemotherapy is associated with elevated DPD levels and chemoresistance pattern. As a newly developed chemotherape...

Full description

Bibliographic Details
Main Authors: Mahshid Mohammadian, Shima Zeynali-Moghaddam, Mohammad Hassan Khadem Ansari, Yousef Rasmi, Anahita Fathi Azarbayjani, Fatemeh Kheradmand
Format: Article
Language:English
Published: Tabriz University of Medical Sciences 2019-08-01
Series:Advanced Pharmaceutical Bulletin
Subjects:
Colorectal cancer
Oxaliplatin
Capecitabine
17-AAG
Dihydropyrimidine dehydrogenase
Online Access:https://apb.tbzmed.ac.ir/PDF/apb-23056

Internet

https://apb.tbzmed.ac.ir/PDF/apb-23056

Similar Items